Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma

HOUSTON--(BUSINESS WIRE) Oct 17, 2023 -- Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials